Pay in 4 interest-free payments of $6.26 Learn more
Ships within 48 hours · Estimated delivery Aug 6 - Aug 11
The complete comparison table Seeing all the data side by side makes the differences clearer
The Clinical Data: Everything Published So Far Phase 1 First-in-Human (Oral Formulation) Published: The Lancet, June 2025 Participants: 144 adults with overweight or obesity (BMI 25.039.9), no diabetes Duration: Up to 12 weeks Dosing: Once-daily oral amycretin, up to 2 50 mg Results: - 50 mg dose: 10.4% mean body weight change - 2 50 mg dose: 13.1% mean body weight change - Placebo: 1.2% 13% weight loss in 12 weeks
They did such an amazing job
Rather than focusing solely on a final weight target, celebrating intermediate achievements supports mental health throughout the journey
Eden Weight Loss employs evidence-based practices and may incorporate medications such as Semaglutide to enhance weight reduction efforts, ensuring that participants receive optimal support throughout their weight loss journey
Clinical data from the SUSTAIN trials supports its dual-function efficacy
